UNH

572.78

+2.13%↑

NVO

127.18

-0.67%↓

JNJ

161.08

+1.05%↑

ABBV

185.58

+1.65%↑

MRK

125.67

-0.33%↓

UNH

572.78

+2.13%↑

NVO

127.18

-0.67%↓

JNJ

161.08

+1.05%↑

ABBV

185.58

+1.65%↑

MRK

125.67

-0.33%↓

UNH

572.78

+2.13%↑

NVO

127.18

-0.67%↓

JNJ

161.08

+1.05%↑

ABBV

185.58

+1.65%↑

MRK

125.67

-0.33%↓

UNH

572.78

+2.13%↑

NVO

127.18

-0.67%↓

JNJ

161.08

+1.05%↑

ABBV

185.58

+1.65%↑

MRK

125.67

-0.33%↓

UNH

572.78

+2.13%↑

NVO

127.18

-0.67%↓

JNJ

161.08

+1.05%↑

ABBV

185.58

+1.65%↑

MRK

125.67

-0.33%↓

Home・Stock List・Eli Lilly and Co.

Eli Lilly and Co.

Closed

Sector Healthcare

802.55 -2.25

Buy Sell

Overview

Share price change

24h

Current

Min

803.49

Max

821.65

Key metrics
By Trading Economics
Income	53M 2.2B
Sales	-583M 8.8B
P/E Sector Avg	134.13 79.786
EPS	2.58
Profit margin	25.575
Employees	43,000
EBITDA	-720M 3.1B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+10.73 upside

Dividends
By Dow Jones
Next Earnings	8 Aug 2024
Next Dividend date	10 Sept 2024
Next Ex Dividend date	15 Aug 2024

Market Stats
By TradingEconomics
Market Cap	51B 906B
Previous open	804.8
Previous close	802.55

News Sentiment

By Acuity

42%

58%

107 / 369 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

N/A / 880.21 Support & Resistance

Eli Lilly and Co. Chart

Related News

8 Jul 2024, 14:15 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Morphic Holding Shares Take Flight on Acquisition by Eli Lilly

8 Jul 2024, 11:15 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Buy Morphic Holding for $3.2 Billion -- Update

8 Jul 2024, 11:05 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Buy Morphic Holding for $3.2 Billion

24 Jun 2024, 17:43 UTC

Major Market Movers

Shares of ResMed, Inspire Medical Down After Eli Lilly Provides Sleep Apnea Study Update

19 Jul 2024, 11:00 UTC

Top News

Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ

19 Jul 2024, 10:50 UTC

Major News Events

Dow Jones Futures: Netflix Subscribers Jump As Tesla, Nvidia Resilient; President Biden Buzz Heats Up -- IBD

16 Jul 2024, 20:04 UTC

Acquisitions, Mergers, Takeovers

Aclaris Therapeutics Received $26.5 M Upfront Plus Is Eligible for Up to $5M in Milestones >ACRS

16 Jul 2024, 20:03 UTC

Acquisitions, Mergers, Takeovers

Aclaris Sells Portion of Future Royalty Payments and Milestones From Eli Lilly on Sales of OLUMIANT for Alopecia Areata to OMERS

15 Jul 2024, 09:30 UTC

Top News

The New Holy Grail for Weight-Loss Drugs Is Sleep Apnea -- WSJ

8 Jul 2024, 20:15 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Snaps Up Morphic For $3.2 Billion; Morphic Stock Hits The Stratosphere -- IBD

8 Jul 2024, 13:53 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Snaps Up Morphic At 79% Premium -- IBD

8 Jul 2024, 12:01 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Snaps Up Morphic At 79% Premium -- IBD

8 Jul 2024, 11:24 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Buy Morphic for $3.2 Billion. Morphic Stock Surges 78%. -- Barrons.com

8 Jul 2024, 10:56 UTC

Acquisitions, Mergers, Takeovers

Morphic's Stock Rockets After $3.2 Billion Buyout Deal With Eli Lilly -- MarketWatch

8 Jul 2024, 10:47 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly: Morphic Transaction Not Subject to Any Financing Condition >LLY

8 Jul 2024, 10:46 UTC

Acquisitions, Mergers, Takeovers

Morphic Holding to Be Acquired for $57/Share; Closed Friday at $31.84 >MORF

8 Jul 2024, 10:45 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Buy Morphic Holding for $57/Share >LLY MORF

8 Jul 2024, 10:45 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Buy Morphic Holding for About $3.2 Billion >LLY MORF

8 Jul 2024, 10:45 UTC

Acquisitions, Mergers, Takeovers

Lilly To Acquire Morphic To Improve Outcomes For Patients With Inflammatory Bowel Disease >LLY MORF

3 Jul 2024, 08:59 UTC

Top News

These Stocks Are Moving the Most Today: Tesla, Paramount, Nvidia, Constellation Brands, and More -- Barrons.com

2 Jul 2024, 19:13 UTC

Top News

Approval of Newest Alzheimer's Drug Will Accelerate New Era of Treatment -- 2nd Update

2 Jul 2024, 17:50 UTC

Top News

Approval of Newest Alzheimer's Drug Will Accelerate New Era of Treatment -- WSJ

27 Jun 2024, 16:01 UTC

Earnings

ResMed Stock Is Down Because of GLP-1 Concerns. It Shouldn't Be. -- Barrons.com

26 Jun 2024, 11:00 UTC

Top News

Acquisitions, Mergers, Takeovers

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24 Jun 2024, 17:28 UTC

Major Market Movers

ResMed, Inspire Medical Shares Down After Eli Lilly Provides Sleep Apnea Study Update

20 Jun 2024, 20:16 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 Jun 2024, 18:51 UTC

Earnings

Obesity-Drug Developers Look at What's Next for a $100 Billion Market -- Barrons.com

20 Jun 2024, 18:09 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 Jun 2024, 11:00 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- WSJ

11 Jun 2024, 14:20 UTC

Hot Stocks

Stocks to Watch Tuesday: Apple, Eli Lilly, Coinbase -- WSJ

Peer Comparison

Price change

Eli Lilly and Co. Forecast

Price Target

By TipRanks

10.73% upside

12 Months Forecast

Average 952.16 USD 10.73%

High 1,117 USD

Low 793 USD

Based on 22 Wall Street analysts offering 12 month price targets forEli Lilly and Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

22 ratings

Buy

Hold

Sell

Based on 22 analysts giving stock ratings to Eli Lilly and Co. - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 880.21Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

107 / 369 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Eli Lilly and Co.

Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.